Stay updated with breaking news from Sciences Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.
Insightful Analysis of Exact Sciences Corp's Financial Health and Market Position
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.
Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.53.
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.